Progress in Pediatric Cardiology
Volume 24, Issue 1 , Pages 51-57 , November 2007

Beta-adrenergic receptor blockade and pediatric dilated cardiomyopathy

  • Beth D. Kaufman

      Affiliations

    • Corresponding Author InformationCorresponding author. Heart Transplant Program, Division of Cardiology, Children's Hospital of Philadelphia, 2 Main, Suite 2165, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104-4399, United States. Tel.: +1 215 590 5248; fax: +1 215 590 1340.
    • ,
  • Robert E. Shaddy

References 

  1. Petrofski JA, Koch WJ. The [beta]-adrenergic receptor kinase in heart failure. J Mol Cell Cardiol. 2003;35(10):1167–1174
  2. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001;33(5):887–905
  3. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35(3):569–582
  4. Colucci WS, et al. Adrenergic overload and apoptosis in heart failure: implications for therapy. J Card Fail. 2000;6(2 Suppl 1):1–7
  5. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80(11A):26L–40L
  6. Buchhorn R, et al. Beta-receptor downregulation in congenital heart disease: a risk factor for complications after surgical repair?. Ann Thorac Surg. 2002;73(2):610–613
  7. Buchhorn R, et al. Effects of therapeutic beta blockade on myocardial function and cardiac remodelling in congenital cardiac disease. Cardiol Young. 2003;13(1):36–43
  8. Kozlik-Feldmann R, et al. Distribution of myocardial beta-adrenoceptor subtypes and coupling to the adenylate cyclase in children with congenital heart disease and implications for treatment. J Clin Pharmacol. 1993;33(7):588–595
  9. Waagstein F, et al. Beta-blockers in dilated cardiomyopathies: they work. Eur Heart J. 1983;4(Suppl A):173–178
  10. Eichhorn EJ, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation. 1990;82(2):473–483
  11. Olsen SL, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25(6):1225–1231
  12. Waagstein F, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342(8885):1441–1446
  13. Gilbert EM, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990;88(3):223–229
  14. Shaddy RE, et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant. 1999;18(3):269–274
  15. Bristow MR, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94(11):2807–2816
  16. Packer M, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise [see comments]. Circulation. 1996;94(11):2793–2799
  17. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007
  18. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13
  19. Packer M, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–2199
  20. Sanderson JE, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol. 1999;34(5):1522–1528
  21. Metra M, et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102(5):546–551
  22. Packer M, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141(6):899–907
  23. Poole-Wilson PA, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13
  24. Ghali JK, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002;105(13):1585–1591
  25. Deedwania PC, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J. 2005;149(1):159–167
  26. Flather MD, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225
  27. Sliwa K, et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol. 2004;44(9):1825–1830
  28. Hunt SA, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46(6):1116–1143
  29. Laer S, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J. 2002;143(5):916–922
  30. Buchhorn R, et al. Beta-blocker therapy of severe congestive heart failure in infants with left to right shunts. Am J Cardiol. 1998;81(11):1366–1368
  31. Buchhorn R, et al. Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PRO-INFANT Trial. Congestive heart failure in infants treated with propanol. Int J Cardiol. 2001;79(2–3):167–173
  32. Shaddy RE. Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation. Am Heart J. 1998;136(1):19–21
  33. Shaddy RE, et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J. 1995;129(1):197–199
  34. Lewis AB. Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy. Am Heart J. 1999;138(2 Pt 1):334–338
  35. Bruns LA, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr. 2001;138(4):505–511
  36. Rusconi P, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant. 2004;23(7):832–838
  37. Gachara N, et al. Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: a preliminary report. Indian Heart J. 2001;53(1):74–78
  38. Azeka E, et al. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol. 2002;40(11):2034–2038
  39. Blume ED, et al. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol. 2006;27(3):336–342
  40. Williams RV, Tani LY, Shaddy RE. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant. 2002;21(8):906–909
  41. Greenway SC, Benson LN. The use of carvedilol in pediatric heart failure. Cardiovasc Hematol Disord Drug Targets. 2006;6(1):35–42
  42. Shaddy RE, et al. The pediatric randomized carvedilol trial in children with heart failure: rationale and design. Am Heart J. 2002;144(3):383–389
  43. Wagoner LE, Starling RC, O'Connor CM. Cardiac function and heart failure. J Am Coll Cardiol. 2006;47(11 Suppl):D18–D22
  44. Rosenthal D, et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplant. 2004;23(12):1313–1333
  45. Josephson CB, et al. A case series of systemic right ventricular dysfunction post atrial switch for simple d-transposition of the great arteries: the impact of beta-blockade. Can J Cardiol. 2006;22(9):769–772
  46. Giardini A, et al. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol. 2006;
  47. Doughan AR, McConnell ME, Book WM. Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J Cardiol. 2007;99(5):704–706
  48. Ratnapalan S, et al. Digoxin–carvedilol interactions in children. J Pediatr. 2003;142(5):572–574
  49. Liggett SB, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103(30):11288–11293
  50. Wagoner LE, et al. Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J. 2002;144(5):840–846

PII: S1058-9813(07)00078-1

doi: 10.1016/j.ppedcard.2007.08.004

Progress in Pediatric Cardiology
Volume 24, Issue 1 , Pages 51-57 , November 2007

Article Tools